Stock·NASDAQ·Consumer Cyclical
Crocs Inc (CROX)
- Market cap
- $5.90B
- P/E
- 10.65
- Dividend yield
- 0.00%
- Street target
- $150.00median of 15 analysts
- 52-week range
- $73.21 $141.28
The short version
Where CROX stands today, in four lines, and what CleaRank Financial AI makes of it.
CROX at a glance
Crocs Inc (CROX): Buy, 73/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($121.40 and $107.93).
- Earnings CROX beat estimates in 7 of its last 7 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $11.6M and bought $1.2M over the last 18 months.
- Valuation P/E of 10.6 against 20.8 for the Consumer Cyclical sector: a discount to peers (-49%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Crocs Inc (CROX) Buy with a model score of 73/100.
Trend is the biggest support: the price is 14.09% above its 200-day average and 1.43% above its 50-day average, while the 50-day average is 12.48% above the 200-day. Slow revenue growth is the biggest drag, with revenue up 2.60%, 4.6 percentage points slower than the sector median. The 50-day average is $121.40 and the 200-day is $107.93. Across the past year the price gained 48.09%.
Only on CleaRank
Figures we compute ourselves from CROX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $123.14 is 1.4% above the 50-day simple moving average of $121.40.Price above its 200-day average ›
The price is 14.1% above the 200-day simple moving average of $107.93.50-day average above the 200-day ›
The 50-day average ($121.40) is 12.5% above the 200-day average ($107.93), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 73% of its 52-week range, between $73.21 and $141.28.
CROX share price
Pick a period: each tab shows how far CROX has moved over it, to the last close.
Today's trading
Where CROX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 10.65 is 48.8% below the Consumer Cyclical median of 20.8.P/S below the sector median ›
The price-to-sales ratio of 1.44 is 24.4% below the sector median of 1.9.Profitable over the last 12 months ›
Net income over the last 12 months was $593.4M on revenue of $4.1B, a net margin of 14.6%.Beat estimates in most recent reports ›
CROX beat the EPS estimate in 7 of its last 7 reports.
Key statistics
The headline figures for CROX.
As of October 17, 2026, CROX trades at $123.14, with a market value of $5.90B and a P/E ratio of 10.65.
What the numbers say
CleaRank Financial AI's reading of CROX's valuation, growth and risks.
Crocs Inc (CROX) has a trailing P/E of 10.65, which is 48.8% below the Consumer Cyclical median of 20.8. The peer comparison on this page rates that as a discount to peers. On sales, CROX trades at 1.44 times, 24.2% below the sector median of 1.9. Trailing earnings stand at $11.41 a share.
With revenue growth of 2.60%, CROX is 4.6 percentage points slower than the sector median of 7.2%. Profitability shows a net margin of 14.64% and an operating margin of 24.22%, with a return on equity of 42.30%, above the sector median of 12.4%. The balance sheet rounds out the picture, with debt-to-equity of 1.22.
CROX reported EPS of $4.55 against the $4.35 analysts had expected, a beat of 4.60% in the July 30, 2026 report. Investors responded positively, and the stock rose 3.52% in the next session.
CROX has beaten the EPS estimate in each of its last 7 reports, yet those beats have not always lifted the shares: the stock fell the next session after 4 of them. Analysts expect EPS of $13.95 this fiscal year and $14.95 next, with the current year showing growth of 11.5%.
CROX typically moves about 2.58% on an average day. Over the last 18 months, insiders sold $11.6M of stock and bought $1.2M. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than open-market purchases.
CROX against the Consumer Cyclical sector
How CROX compares with the median Consumer Cyclical stock CleaRank tracks.
Price to earnings vs sector: CROX trades at a notable discount to sector peers (-49%), which may indicate undervaluation or specific company headwinds.
Return vs SPY: Since May 6, 2025, CROX has gained 24.7% against a gain of 36.6% for SPY.
Performance against SPY
CROX and the Consumer Cyclical sector fund over the same days.
Revenue and earnings
How much CROX sells, and how much of it becomes profit.
Revenue growth: Revenue fell 1.5% in FY2025 to $4.0B, from $4.1B a year earlier.
Profit margin: The net margin was -2.0% in FY2025, down from 23.2% the year before.
Loss-making: CROX lost $81.2M in FY2025.
Earnings reality check
Did CROX beat what analysts expected, and how did the stock react?
Earnings record: CROX beat the analyst estimate in 7 of the last 7 quarters.
Market reaction: The stock fell in the first session after 4 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 30, 2026after close | $4.35 | $4.55 | +4.60% | +3.52% | +8.51% |
| Apr 30, 2026after close | $2.79 | $2.99 | +7.17% | +1.86% | +2.06% |
| Oct 30, 2025after close | $2.36 | $2.92 | +23.73% | -1.03% | -4.98% |
| Aug 7, 2025after close | $4.02 | $4.23 | +5.22% | +1.14% | +12.96% |
| May 8, 2025after close | $2.49 | $3.00 | +20.48% | -0.80% | +5.98% |
| Feb 13, 2025after close | $2.26 | $2.52 | +11.50% | -1.47% | -2.23% |
| Oct 29, 2024after close | $3.11 | $3.60 | +15.76% | -2.31% | -5.70% |
As of October 17, 2026, CROX has beaten the analyst EPS estimate in 7 of its last 7 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 30, 2026, came in 4.60% above the estimate and the stock moved +3.52% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 55.6, in neutral territory.RSI above 50 ›
An RSI of 55.6 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of CROX
The score, the reasoning behind it, and what could move the price next.
CROX is trending up. At $123.14, the stock sits 1.43% above its 50-day average of $121.40 and 14.09% above its 200-day average of $107.93. Within its 52-week range, the price is 12.84% below the high of $141.28 and 68.20% above the low of $73.21, which places it near the top of that band.
Short-term and long-term readings disagree. Over the past month the price climbed 6.71%, but over the past three months it dropped 10.20%, while the past year shows a gain of 48.09%. The 14-day RSI sits at 55.6, which is neutral territory, and the MACD line is negative.
Earnings beat ›
The July 30, 2026 report beat the EPS estimate by 4.60%, and the share price rose 3.52% in the first session after it.
Source: Earnings report, July 30, 2026Analyst upgrade ›
Piper Sandler upgraded it to Overweight from Neutral on June 26, 2026.
Source: Analyst action, Piper Sandler, June 26, 2026
Rating reaffirmed ›
UBS kept its Neutral rating on July 31, 2026.
Source: Analyst action, UBS, July 31, 2026
- Two levels matter most: the 52-week high at $141.28 above the price, and the 50-day SMA at $121.40 below it.
- A 14-day RSI of 55.6 falls in the neutral zone, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- CROX rose 3.52% in the first session after its July 30, 2026 report, and it has beaten estimates in 7 of the last 7 reports.
CROX's uptrend depends on the price holding above its 50-day average of $121.40 and its 200-day average of $107.93. A close below the 50-day would be the first sign of weakness. If the shares pull back, the 50-day SMA at $121.40 is the first level they would reach.
The next level overhead for CROX is the 52-week high at $141.28.
Technical indicators
Momentum and trend for CROX, from its daily closes.
As of October 17, 2026, with CROX at $123.14, its 14-day RSI is 55.6 (neutral territory), its 50-day simple moving average is $121.40 and its 200-day is $107.93.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CROX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, CROX's 1-year correlation of daily returns is +0.31 with S&P 500 (SPY), +0.25 with Nasdaq 100 (QQQ), +0.05 with Bitcoin (BTC) and -0.01 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
7 of 15 analysts rate it a buy or strong buy, 7 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $150.00 is 21.8% above the price.More buy ratings than three months ago ›
7 of 15 rate it a buy now, against 7 of 15 three months ago.
CROX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 31, 2026 | UBS | Maintains | Neutral |
| Jul 31, 2026 | Barclays | Maintains | Equal-Weight |
| Jul 23, 2026 | B of A Securities | Maintains | Buy |
| Jul 20, 2026 | Seaport Global | Maintains | Buy |
| Jun 26, 2026 | Piper Sandler | Upgrade | Overweight |
| Jun 15, 2026 | Stifel | Maintains | Hold |
As of October 17, 2026, 15 Wall Street analysts cover CROX: 7 rate it a buy or strong buy, 7 a hold and 1 a sell or strong sell. Their 12-month price targets range from $95.00 to $163.00, with a median of $150.00, 21.8% above the price of $123.14.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CROX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CROX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CROX tends to move, against the market and on its own.
The long record
CROX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 2.58% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 73.2%, from January 2020 to March 2020, regained by September 2020.Most 1-year holds ended higher ›
72% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $152,401, against $42,058 in the S&P 500 (SPY).
CROX Drawdowns & Recovery
As of October 17, 2026, CROX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -73.2% (January 2020 to March 2020); it regained that peak by September 2020, 6 months after the low, and 72% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CROX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CROX beat the S&P 500 over this period: $152,401 against $42,058.
A $10,000 investment in CROX in October 2016 would be worth about $152,401 today with dividends reinvested, compared with about $42,058 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CROX, and which have not.
Strongest month, November: an average of +9.08%, up in 6 of 10 years.
Weakest month, March: an average of -2.56%, up in 5 of 10 years.
This month, October: has averaged +7.18%, up in 7 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CROX's strongest calendar month has been November (average +9.08%, up in 6 of 10 years) and its weakest March (average -2.56%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CROX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CROX today could grow to about $29,449 by 2036 in the base case, with a 90th-percentile outcome near $223,415 and a 10th-percentile outcome around $3,882. Projections are statistical simulations, not guarantees.
CROX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $190 for CROX by 2030 in the base case, from $123 today (1.5x over 4 years). The 10th-percentile path ends near $52.65. These are outcomes of a Monte Carlo simulation run on CROX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $72.28 | $137 | $260 | |
| 2028 | $61.75 | $153 | $378 | |
| 2029 | $56.12 | $170 | $517 | |
| 2030 | $52.65 | $190 | $683 | |
| 2031 | $50.42 | $211 | $886 |
Method: a lognormal simulation of CROX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. CROX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
CROX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1.2M on the open market and sold $11.6M.
As of October 17, 2026, CROX insiders reported 7 open-market sales worth $11.6M and 6 open-market purchases worth $1.2M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Beth Janell Kaplan
Director
|
Buy | 885 | $99.2K |
| Sep 15, 2026 | Thomas J Smach
Director
|
Buy | 680 | $75.8K |
| Sep 10, 2026 | Thomas J Smach
Director
|
Buy | 4.0K | $437.5K |
| Aug 10, 2026 | Andrew Vivian Rees
Chief Executive Officer
|
Sell | 30.0K | $4.2M |
| Aug 4, 2026 | Andrew Vivian Rees
Chief Executive Officer
|
Option | 200.0K | $1.4M |
| Jun 9, 2026 | Ian M Bickley
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | Ronald L Frasch
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | Charisse Ford Hughes
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | Beth Janell Kaplan
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | John B Replogle
Director
|
Grant | 1.3K | - |
| Jun 9, 2026 | Thomas J Smach
Director
|
Grant | 4.1K | - |
| Jun 9, 2026 | Neeraj Tolmare
Director
|
Grant | 2.3K | - |
| Jun 9, 2026 | Douglas J Treff
Director
|
Grant | 2.5K | - |
| Jun 5, 2026 | Andrew Vivian Rees
Chief Executive Officer
|
Sell | 32.7K | $3.9M |
| May 22, 2026 | Ronald L Frasch
Director
|
Grant | 500 | - |
| Mar 10, 2026 | Rupert George Campbell
Officer
|
Grant | 38.7K | - |
| Mar 10, 2026 | Anne Mehlman
Officer
|
Grant | 68.3K | - |
| Mar 10, 2026 | Patraic Reagan
Chief Financial Officer
|
Grant | 44.2K | - |
| Mar 10, 2026 | Andrew Vivian Rees
Chief Executive Officer
|
Grant | 207.9K | - |
| Mar 10, 2026 | Terence Reilly
Officer
|
Grant | 44.2K | - |
| Feb 20, 2026 | Anne Mehlman
Officer
|
Sell | 12.1K | $1.2M |
| Feb 20, 2026 | Thomas J Smach
Director
|
Sell | 5.0K | $496.3K |
| Feb 13, 2026 | Thomas J Smach
Director
|
Sell | 5.0K | $492.1K |
| Nov 20, 2025 | Andrew Vivian Rees
Chief Executive Officer
|
Grant | 40.0K | - |
| Nov 11, 2025 | John B Replogle
Director
|
Buy | 3.0K | $223.5K |
| Sep 22, 2025 | Patraic Reagan
Chief Financial Officer
|
Grant | 45.4K | - |
| Aug 12, 2025 | Susan L Healy
Chief Financial Officer
|
Buy | 2.0K | $153.1K |
| Aug 8, 2025 | John B Replogle
Director
|
Buy | 3.3K | $250.1K |
| Jun 10, 2025 | Ian M Bickley
Director
|
Grant | 2.9K | - |
| Jun 10, 2025 | Ronald L Frasch
Director
|
Grant | 1.5K | - |
| Jun 10, 2025 | Charisse Ford Hughes
Director
|
Grant | 2.9K | - |
| Jun 10, 2025 | Beth Janell Kaplan
Director
|
Grant | 1.5K | - |
| Jun 10, 2025 | John B Replogle
Director
|
Grant | 2.9K | - |
| Jun 10, 2025 | Thomas J Smach
Director
|
Grant | 5.0K | - |
| Jun 10, 2025 | Neeraj Tolmare
Director
|
Grant | 2.9K | - |
| Jun 10, 2025 | Douglas J Treff
Director
|
Grant | 3.1K | - |
| May 12, 2025 | Ian M Bickley
Director
|
Sell | 3.0K | $352.8K |
| May 9, 2025 | Thomas J Smach
Director
|
Sell | 9.1K | $1.0M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.